Zydus Lifesciences to Introduce Advanced Cancer Tests in India

Exclusive Deal with Myriad Genetics
 
Zydus Lifesciences has signed an exclusive agreement with US-based Myriad Genetics to introduce advanced cancer risk and tumour diagnostic tests in the Indian market. 

Three Key Tests Coming Soon
 The agreement includes MyRisk® hereditary cancer test, MyChoice® HRD Plus, and Prolaris® prostate cancer test, helping doctors assess risk and guide treatment decisions. 

Boost to Cancer Care in India

These tests support personalised, evidence-based cancer care and can help patients and clinicians make better treatment decisions earlier. 

Click Here

Healthcare Impact

The partnership strengthens precision diagnostics availability in India, potentially improving early detection and long-term outcomes. 

With Our Subscription Plans

Open demat account in 5 minutes*

Open Demat A/C
G-L92HWH8MZR